Join
Live feed
·
PRReleasevia Quantisnow
HUTCHMED (China) Limited logo

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

ByQuantisnow·Wall Street's wire, on your screen.
HCM· HUTCHMED (China) Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HCM (HUTCHMED (China) Limited) and more on Quantisnow.